Triochem Products Limited Re-submits Q3FY26 Unaudited Standalone Financial Results After Correcting Typographical Error
Triochem Products Limited re-submitted its Q3FY26 unaudited standalone financial results after correcting a typographical error in the Limited Review Report following BSE's regulatory observation. The company reported a net loss of Rs. 13.18 lakhs for Q3FY26 compared to a profit of Rs. 8.83 lakhs in Q3FY25, with total income declining to Rs. 22.06 lakhs from Rs. 45.85 lakhs year-over-year. The Board approved asset sales worth over Rs. 1,100 lakhs in fair market value to support future business ventures.

*this image is generated using AI for illustrative purposes only.
Triochem Products Limited has re-submitted its unaudited standalone financial results for the quarter and nine months ended 31st December 2025 to BSE Limited, following regulatory observations regarding a typographical error in the Limited Review Report. The pharmaceutical company corrected the period mentioned in the report from December 31, 2024 to December 31, 2025.
Financial Performance Overview
The company's financial performance for Q3FY26 showed challenging results across key metrics:
| Metric | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Total Income | Rs. 22.06 lakhs | Rs. 45.85 lakhs | -51.9% |
| Net Loss/Profit | Rs. (13.18) lakhs | Rs. 8.83 lakhs | Loss |
| Basic EPS | Rs. (5.38) | Rs. 3.60 | Negative |
For the nine-month period ended December 31, 2025, the company reported a net loss of Rs. 35.50 lakhs compared to a net profit of Rs. 5.17 lakhs in the corresponding period of the previous year.
Regulatory Compliance and Re-submission
BSE Limited had issued a non-compliance notice dated 20th February 2026 under Regulation 33 of SEBI (LODR) Regulations, 2015, highlighting the typographical error in the Limited Review Report. The company acknowledged the error and confirmed that there were no changes in the actual financial results, only the correction of the wrong period mentioned in the auditor's report.
The Board of Directors approved the financial results at its meeting held on Friday, 13th February 2026, with Mr. Ramu S. Deora, Director, serving as the Chairperson of the meeting.
Operational and Strategic Developments
The company operates in a single segment of chemicals and pharmaceuticals. During the period, Triochem Products received shareholder approval on 13th December 2025 for the sale of immovable properties, plant & machinery, and investment property situated in Maharashtra.
| Asset Sale Details | Value |
|---|---|
| Written Down Value | Rs. 56.92 lakhs |
| Fair Market Value (P&M) | Rs. 672.05 lakhs |
| Fair Market Value (Investment Property) | Rs. 509.00 lakhs |
The assets have been classified as 'Assets Held for Sale' in accordance with Ind AS 105, with the transaction expected to be completed on or before 31st March 2026. The proceeds are intended for new business ventures and strategic initiatives.
Expense Analysis
The company's expense structure for Q3FY26 included employee benefit expenses of Rs. 14.44 lakhs, other expenditure of Rs. 23.62 lakhs, and depreciation expenses of Rs. 1.36 lakhs, totaling Rs. 39.42 lakhs against total income of Rs. 22.06 lakhs.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors Kanu Doshi Associates LLP providing an unqualified review conclusion on the statements.
Historical Stock Returns for Triochem Products
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
































